Lobeline - Yaupon Therapeutics
Latest Information Update: 02 Oct 2021
At a glance
- Originator Yaupon Therapeutics
- Developer National Institute of Mental Health
- Class Alkaloids; Drug withdrawal therapies; Piperidines; Smoking cessation therapies
- Mechanism of Action Dopamine release inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Substance-related disorders
Most Recent Events
- 02 Nov 2006 Phase-II clinical trials in Substance-related disorders in USA (unspecified route)
- 02 Nov 2004 Phase-I clinical trials in Substance-related disorders in USA (unspecified route)
- 02 Nov 2004 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)